BioSpace News Archive

Amphastar Pharmaceuticals, Inc., announces that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Epinephrine Injection, USP 30mg/30mL Multiple Dose Vial.

Verastem, Inc. announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant advanced solid tumors.

EOS imaging, a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, was notified by Alphatec Holdings, Inc.

BioAegis Therapeutics Inc. has highlighted recently published gene expression data in animal studies where recombinant human plasma gelsolin significantly increased survival in pneumonia due to severe influenza.

Dr. Reddy’s Laboratories Ltd. announced the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor® Tablets, approved by the U.S. Food and Drug Administration.

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological therapeutic products, cordially invites investors, the media, and the public to join a signing ceremony and analyst & investor call on Thursday, April 30, 2020.

Statistically significant improvement in Alzheimer’s disease agitation, as measured by the CMAI total score compared to placebo (p=0.010, primary endpoint)

TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, and Imperial College London, a public research university located in the United Kingdom, announced that they have entered into a partnership in which TriLink will manufacture self-amplifying RNA for COVID-19 vaccine development.

Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the appointment of Joe Miller as Chief Financial Officer.

Magellan Health, Inc. announced that it will report its earnings for the first quarter ended on March 31, 2020 at approximately 6:30 a.m. Eastern on Monday, May 11, 2020. At 8 a.m. Eastern on the same day, Magellan’s management will host a conference call and webcast to discuss earnings and other information.